Lilly to present new data for Taltz and Mirikizumab

[Fred]

Lilly have said they will be presenting new Taltz data and Phase 2 efficacy, safety and patient-reported outcomes data for mirikizumab in moderate-to-severe plaque psoriasis. at the American Academy of Dermatology (AAD) annual meeting taking place Feb. 16-20, 2018.

Quote:

---

Eli Lilly announced that it will present new data for Taltz® (ixekizumab) at the American Academy of Dermatology (AAD) annual meeting taking place Feb. 16-20, 2018, in San Diego, Calif.

The data include eight abstracts for Taltz, featuring two oral presentations highlighting patient-reported outcomes from a Phase 3 clinical trial evaluating Taltz for the treatment of moderate-to-severe genital psoriasis, as well as findings from the Corrona Psoriasis Registry on Taltz patient clinical characteristics and treatment history. Two abstracts evaluating the efficacy and safety of Taltz for the treatment of active psoriatic arthritis will also be presented.

Additionally, Lilly will present Phase 2 efficacy, safety and patient-reported outcomes data for mirikizumab in moderate-to-severe plaque psoriasis. One abstract from the Closer Together Survey, a survey where nearly 2,000 people with moderate-to-severe psoriasis from 17 countries cross Europe and Canada shared how psoriasis impacts their quality of life and their overall satisfaction with treatment, will also be presented.

Source: lilly.com

[jiml]

That's interesting to read about the Taltz but also interesting the mirikizumab phase 2 study of efficacy of it for moderate to severe psoriasis ....I see it targets IL-23 so could show good results

It looks as if Eli Lilly will be doing some interesting presentations including on quality of life for sufferers at the meeting